Choice of Treatment for Stage IA Non-small Cell Lung Cancer Patients Ineligible for Surgery: Ablation or Stereotactic Body Radiotherapy?

Long Liang, Guoshu Li, Shuanshuan Xie, Guifeng Sun, Mengmei Zhang, Fenyong Sun, Aimei PengJournal of Cancer 2020 · DOI

TL;DR

For patients with early-stage, inoperable non-small cell lung cancer (NSCLC), this large-scale study found no significant difference in overall survival between two non-surgical treatment options: ablation and stereotactic body radiotherapy (SBRT). This suggests that quality of life and patient preference may be key factors in choosing between these effective treatments.

What Problem Does This Paper Address?

Surgery is the gold standard for treating early-stage non-small cell lung cancer (NSCLC). However, a significant portion of patients (over 20%) are deemed inoperable due to factors like age, poor lung function, or other health conditions. For these patients, alternative treatments are crucial. Two prominent options are stereotactic body radiotherapy (SBRT), a highly focused form of radiation therapy, and ablation techniques (like laser, cryotherapy, or electrocautery), which destroy tumor tissue. While both aim for local control, there's been a lack of large-scale, comparative studies to guide treatment decisions for inoperable stage IA NSCLC patients, leaving a gap in evidence-based recommendations.

Methods

The researchers utilized the Surveillance, Epidemiology, and End Results (SEER) database, a comprehensive US cancer registry, to identify a cohort of 6,395 patients diagnosed with stage IA NSCLC between 2004 and 2015 who were treated with either SBRT or ablation as their primary therapy.

To account for potential differences in patient characteristics between the two treatment groups, they employed propensity score methods. This statistical technique helps to balance the groups on observed covariates, making the comparison more robust. Kaplan-Meier analysis was used to compare survival curves, and Cox regression analysis was performed to assess the balance of baseline covariates after adjustment.

Datasets

The study exclusively used the Surveillance, Epidemiology, and End Results (SEER) database. This database contains information on approximately 10% of the US population and includes data on patient survival, pathological type, disease stage, and treatment. No new datasets were introduced.

Key Insights and Ideas

  • Non-inferiority of Ablation: The study strongly suggests that ablation is a non-inferior treatment option to SBRT in terms of survival for inoperable stage IA NSCLC. This is a critical finding for patients who may not be candidates for SBRT or who prefer less invasive options.
  • Quality of Life as a Deciding Factor: Given the similar survival outcomes, the authors highlight that factors like quality of life and patient preference are likely to become more important in choosing between SBRT and ablation. This shifts the focus from purely survival metrics to a more holistic patient-centered approach.
  • SEER Database Utility: The study demonstrates the power of large, population-based databases like SEER for answering important clinical questions when randomized controlled trials are scarce or impractical.

Key Results

  • No Significant Survival Difference: Kaplan-Meier analysis showed no statistically significant difference in overall survival (OS) between patients treated with ablation and those treated with SBRT (log-rank p>0.05).
  • Hazard Ratios: On univariate analysis, the hazard ratio (HR) for OS in the ablation group compared to the SBRT group was 0.930 (95% CI: 0.817–1.058, p=0.269). In multivariate analysis, the HR was 0.974 (95% CI: 0.858–1.105, p=0.680). Both results indicate no significant difference in survival.
  • Subtype Analysis: Similar non-significant differences in survival were observed when analyzing specific subtypes of NSCLC, including squamous cell carcinoma (SQCC) and adenocarcinoma (AD).
  • Mortality and Median Survival: The overall lung cancer-specific mortality rate was 29.5%. While the ablation group had a slightly higher mortality rate (37.6%) compared to the SBRT group (29.0%), their median survival was longer (31 months vs. 20 months). However, these differences were not statistically significant in the adjusted analyses.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Nature: The study is retrospective, meaning it relies on existing data, and factors not captured in the SEER database could influence outcomes.
  • Lack of Detailed Data: The SEER database does not provide granular information on radiation dose, specific toxicities, pulmonary function, cause of death, or local progression-free survival, which could offer deeper insights.
  • Ablation Technique Variability: The study groups "ablation" broadly, without differentiating between specific techniques (e.g., laser, cryotherapy, electrocautery) or approaches (surgical, percutaneous, bronchoscopic).

Future research directions suggested include:

  • Prospective Trials: The need for prospective, randomized trials to definitively compare SBRT and ablation.
  • Quality of Life Studies: Investigating quality of life and patient-reported outcomes to better inform treatment choices.
  • Detailed Ablation Technique Comparison: Further research into the specific outcomes and complications associated with different ablation modalities.

Summary updated

Abstract

<b>Purpose</b>: To compare the survival outcomes of ablation and stereotactic body radiotherapy (SBRT) in inoperable patients with stage IA non-small cell lung cancer (NSCLC). <b>Patients and Methods</b>: Using the Surveillance, Epidemiology, and End Results (SEER) database, we identified 6,395 patients with stage IA NSCLC who had complete clinical information from 2004 to 2015. Kaplan-Meier analysis was performed to determine the propensity score based on the clinical characteristics of patients with stage IA NSCLC. Overall survival (OS) was compared between patients with stage IA NSCLC who were treated with ablation and SBRT after adjusting, stratifying, or matching. <b>Results</b>: Kaplan-Meier analysis demonstrated no significant difference in survival curves (log-rank, <i>p</i>>0.05) between the ablation and SBRT groups. Compared with the SBRT group, the hazard ratio (HR) (95% confidence interval [CI]) of OS was 0.930 (0.817-1.058, <i>p</i>=0.269) in the ablation group on univariate analysis. On multivariate analysis, similar effects on OS (HR: 0.974, 95% CI: 0.858-1.105, <i>p</i>=0.680) were seen in patients with stage IA NSCLC in both the groups. <b>Conclusions</b>: This study suggests that survival does not differ significantly between patients with stage IA NSCLC treated with ablation and SBRT. These results will be helpful for patients with stage IA NSCLC who are ineligible for surgery.
BibTeX
@article{liang2020choice,
  author = {Long Liang and Guoshu Li and Shuanshuan Xie and Guifeng Sun and Mengmei Zhang and Fenyong Sun and Aimei Peng},
  title = {{Choice of Treatment for Stage IA Non-small Cell Lung Cancer Patients Ineligible for Surgery: Ablation or Stereotactic Body Radiotherapy?}},
  journal = {Journal of Cancer},
  year = {2020},
  doi = {10.7150/jca.39465},
}
Figure